Scilex控股公司恢复了对Nasdaq的遵守,并将Oramed纸条到期期限延长至2025年。 Scilex Holding Company regains Nasdaq compliance and extends Oramed note maturity to 2025.

Scilex控股公司在提交最新季度报告后恢复遵守Nasdaq规则。 Scilex Holding Company has regained compliance with Nasdaq rules after filing its latest quarterly report. 该公司的重点是非类阿片止痛管理,还将其通知的成熟日期延长到2025年12月31日,即Oramed制药公司。 The company, which focuses on non-opioid pain management, has also extended the maturity date of its note to Oramed Pharmaceuticals to December 31, 2025. Scilex的产品包括神经病痛、偏头痛和痛风的治疗,还有各种疼痛条件的其他候选者正在发展之中。 Scilex's products include treatments for neuropathic pain, migraines, and gout, with further candidates in development for various pain conditions.